Potential Biomarkers for Early Diagnosis of Acute Aortic Dissection

Status Unknown status

Clinical Trial Summary

Acute aortic dissection (AAD) is an acute vascular lesions with high early misdiagnosis rate(31.8%), and mortality rate was 38%. In recent years, the incidence is rising and serious threat to human health. At present, the clinical diagnosis of AAD commonly used imaging methods, including chest X-ray, B ultrasound, CT, MRI and aortic angiography. Chest X-ray and two-dimensional ultrasound is limited in diagnosis of AAD, esophageal ultrasonography can display the intimal, identify the true and false lumen, but greater risk. CT, MRI and aortic angiography can be used as diagnosis method, but time-consuming, expensive and requires handling patients in emergency situations, should not be used as the preferred. Therefore, it is significance that biomarkers with high specificity and sensitivity for clinical fast diagnosis of AAD.

Parts small sample tests found that single serum α-smooth muscle actin (α-SMA), myosin heavy chain(MHC) and human soluble elastin fragments (sELAF) levels in patients with AAD were significantly higher than that of others (normal people, acute myocardial infarction patients). But because of the small study sample, limited control risk factors and incomplete comparison, their conclusions were questionable. In our previous studies also found that serum α-SMA, MHC and sELAF levels and the pathogenesis of AAD and prognosis are closely related. Therefore, on the basis, a prospective study is needed. We observe all the three biomarkers in enrolled patients with acute chest pain in emergency department, levels in healthy volunteers as the blank control. Then make definite diagnosis of the enrolled patients, and further observe the biomarkers dynamic change in AAD. Lastly, evaluate the early diagnostic value of combination serum α-SMA, MHC and sELAF level on patients with AAD.

Clinical Trial Description

This is a prospective clinical study designed to procure blood samples from patients who present to the Emergency Department with suspected AAD.

Subjects enrolled in this study will sign and informed consent and have 3 blood samples drawn at different time points during their emergency department visit. In addition, data will be collected about the patient's health history, hospital procedures, and final diagnosis.

Blood samples collected in this study will be sent to laboratory for long-term storage and analysis in the future for these blood markers as they become available. No genetic testing will be conducted on these samples. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01860768
Study type	Observational
Source	Central South University
Contact	CHAI Xiangping, MD
Phone	+86-13787204259
Email	fenghuaxuepiao@qq.com
Status	Unknown status
Phase	N/A
Start date	May 2013
Completion date	April 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05582967` - The DAShED (Diagnosis of Aortic Syndrome in the ED) Study
Terminated	`NCT04116684` - Digital Home Blood Pressure Monitoring in Type B Aortic Dissection Patients	N/A
Completed	`NCT02086136` - Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection
Recruiting	`NCT02201589` - Feasibility of Endovascular Repair Of Ascending Aortic Pathologies	N/A
Recruiting	`NCT03948555` - Magnetic Resonance Imaging (MRI) for Aortic Dissection to Visualise Inflammation
Enrolling by invitation	`NCT05912608` - Optimal Strategy for Repair of Type A Acute Aortic Dissection
Recruiting	`NCT03707743` - Registry of Patients With Acute/Subacute Type B Aortic Dissection Treated by Means of the STABILISE Technique (STABILISE)
Enrolling by invitation	`NCT00583817` - Endovascular Treatment of Thoracic Aortic Disease	N/A
Recruiting	`NCT05073991` - Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR.
Not yet recruiting	`NCT02523300` - Glucocorticoid on the Prognosis of TEVAR	N/A
Completed	`NCT01197651` - Aortic-Stent-Register	N/A
Recruiting	`NCT04471909` - NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness	N/A
Not yet recruiting	`NCT06044259` - Study Comparing Hemiarch Replacement and Hemiarch Plus Stent Implantation in Acute Aortic Dissection	N/A
Completed	`NCT05039814` - Prediction of Postoperative Acute Kidney Injury in Patients With Acute Type A Aortic Dissection Using Cystatin C
Recruiting	`NCT03780738` - A Validation Study of The Relationship Between ALDH2 and Aortic Dissection
Completed	`NCT03647566` - 18F Sodium Fluoride PET/CT in Acute Aortic Syndrome
Enrolling by invitation	`NCT05800743` - Evaluation of the GORE® Ascending Stent Graft	N/A
Recruiting	`NCT03347812` - Clinical Study for Evaluating the Safety and Efficacy of Total Endovascular Aortic Arch Repair	N/A
Completed	`NCT05044494` - Surgery for Delay-recognized or Defer-operated Type A Aortic Dissection
Terminated	`NCT02958098` - My Research Legacy Pilot Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.